123 related articles for article (PubMed ID: 38524525)
1. Extended survival with metastatic pancreatic cancer under fruquintinib treatment after failed chemotherapy: Two case reports.
Wu D; Wang Q; Yan S; Sun X; Qin Y; Yuan M; Wang NY; Huang XT
World J Clin Cases; 2024 Mar; 12(7):1296-1304. PubMed ID: 38524525
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer: results of a single-arm, single-center, prospective, phase II clinical study.
Ma S; Chen R; Duan L; Li C; Yang T; Wang J; Zhao D
J Gastrointest Oncol; 2023 Apr; 14(2):1052-1063. PubMed ID: 37201046
[TBL] [Abstract][Full Text] [Related]
3. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial.
Li J; Qin S; Xu RH; Shen L; Xu J; Bai Y; Yang L; Deng Y; Chen ZD; Zhong H; Pan H; Guo W; Shu Y; Yuan Y; Zhou J; Xu N; Liu T; Ma D; Wu C; Cheng Y; Chen D; Li W; Sun S; Yu Z; Cao P; Chen H; Wang J; Wang S; Wang H; Fan S; Hua Y; Su W
JAMA; 2018 Jun; 319(24):2486-2496. PubMed ID: 29946728
[TBL] [Abstract][Full Text] [Related]
4. Significant response from fruquintinib plus anti-PD-1 immunotherapy for microsatellite stable metastatic colorectal cancer with liver and lung metastasis in the third line: case report.
He L; Cheng X; Zhou C; Li Q; Zhang B; Cheng X; Donadon M; Mannavola F; Tu S
J Gastrointest Oncol; 2023 Dec; 14(6):2617-2626. PubMed ID: 38196522
[TBL] [Abstract][Full Text] [Related]
5. Using a combination of fruquintinib, raltitrexed, and S-1 as a third-line treatment for metastatic colorectal cancer with co-existence of Hodgkin lymphoma: a case report.
Wan Y; Luo D
J Gastrointest Oncol; 2023 Feb; 14(1):450-457. PubMed ID: 36915460
[TBL] [Abstract][Full Text] [Related]
6. Sequence Therapy with FOLFIRINOX and Gemcitabine/Nab-Paclitaxel for Patients with Advanced Pancreatic Cancer: A Monocentre Retrospective Cohort Study.
Queck A; Elango S; Koch C; Walter D; Schmidt J; Trebicka J; Trojan J; Pession U; Finkelmeier F; Waidmann O
Oncol Res Treat; 2022; 45(3):79-87. PubMed ID: 34875671
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study.
Deng YY; Zhang XY; Zhu PF; Lu HR; Liu Q; Pan SY; Chen ZL; Yang L
Front Oncol; 2023; 13():1097911. PubMed ID: 36937443
[TBL] [Abstract][Full Text] [Related]
8. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous Non‒Small-Cell Lung Cancer.
Lu S; Chang J; Liu X; Shi J; Lu Y; Li W; Yang JJ; Zhou J; Wang J; An T; Yang L; Liu Z; Zhou X; Chen M; Hua Y; Su W
J Clin Oncol; 2018 Apr; 36(12):1207-1217. PubMed ID: 29528793
[TBL] [Abstract][Full Text] [Related]
9. A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer - The FALUCA study.
Lu S; Chen G; Sun Y; Sun S; Chang J; Yao Y; Chen Z; Ye F; Lu J; Shi J; He J; Liu X; Zhang Y; Liu Z; Fang J; Cheng Y; Hu C; Mao W; Hu Y; Gong Y; Shan L; Yang Z; Song Y; Li W; Bai C; Wang B; Ma R; Zheng Z; Liu M; Jie Z; Cao L; Liao W; Pan H; Huang D; Chen Y; Yang J; Qin S; Ma S; Liang L; Liu Z; Zhou J; Tao M; Huang Y; Qiu F; Huang Y; Guan S; Peng M; Su W
Lung Cancer; 2020 Aug; 146():252-262. PubMed ID: 32592986
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, safety, and predictors of fruquintinib plus anti-programmed death receptor-1 (PD-1) antibody in refractory microsatellite stable metastatic colorectal cancer in a real-world setting: a retrospective cohort study.
Yang X; Yin X; Qu X; Guo G; Zeng Y; Liu W; Jagielski M; Liu Z; Zhou H
J Gastrointest Oncol; 2023 Dec; 14(6):2425-2435. PubMed ID: 38196544
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of fruquintinib as third- or further-line therapy for patients with advanced bone and soft tissue sarcoma: a multicenter retrospective study.
Ding X; Liu Y; Zhang Y; Liang J; Li Q; Hu H; Zhou Y
Anticancer Drugs; 2023 Aug; 34(7):877-882. PubMed ID: 36539356
[TBL] [Abstract][Full Text] [Related]
12. Combination of Fruquintinib and Anti-PD-1 for the Treatment of Colorectal Cancer.
Wang Y; Wei B; Gao J; Cai X; Xu L; Zhong H; Wang B; Sun Y; Guo W; Xu Q; Gu Y
J Immunol; 2020 Nov; 205(10):2905-2915. PubMed ID: 33028620
[TBL] [Abstract][Full Text] [Related]
13. Fruquintinib in combination with sintilimab or TAS-102 as third-line or above treatment in patients with metastatic colorectal cancer: a real-world study.
Li L; Wang T; Wu Z; Li Y; Ma H; Wang L; Lei S; Chen W
Transl Cancer Res; 2023 Nov; 12(11):3034-3044. PubMed ID: 38130300
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study.
Xu RH; Li J; Bai Y; Xu J; Liu T; Shen L; Wang L; Pan H; Cao J; Zhang D; Fan S; Hua Y; Su W
J Hematol Oncol; 2017 Jan; 10(1):22. PubMed ID: 28103904
[TBL] [Abstract][Full Text] [Related]
15. Previous Use of Anti-Vascular Endothelial Growth Factor Receptor Agents Decreases Efficacy of Fruquintinib in Metastatic Colorectal Cancer Refractory to Standard Therapies.
Wang L; Cao H; Jiang C; He W; You Y; Peng K; Jin Y; Xia L
Front Oncol; 2020; 10():587692. PubMed ID: 33282739
[TBL] [Abstract][Full Text] [Related]
16. Fruquintinib Enhances the Antitumor Immune Responses of Anti-Programmed Death Receptor-1 in Colorectal Cancer.
Li Q; Cheng X; Zhou C; Tang Y; Li F; Zhang B; Huang T; Wang J; Tu S
Front Oncol; 2022; 12():841977. PubMed ID: 35371995
[TBL] [Abstract][Full Text] [Related]
17. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.
Dasari A; Lonardi S; Garcia-Carbonero R; Elez E; Yoshino T; Sobrero A; Yao J; García-Alfonso P; Kocsis J; Cubillo Gracian A; Sartore-Bianchi A; Satoh T; Randrian V; Tomasek J; Chong G; Paulson AS; Masuishi T; Jones J; Csőszi T; Cremolini C; Ghiringhelli F; Shergill A; Hochster HS; Krauss J; Bassam A; Ducreux M; Elme A; Faugeras L; Kasper S; Van Cutsem E; Arnold D; Nanda S; Yang Z; Schelman WR; Kania M; Tabernero J; Eng C;
Lancet; 2023 Jul; 402(10395):41-53. PubMed ID: 37331369
[TBL] [Abstract][Full Text] [Related]
18. Fruquintinib for refractory colorectal cancer in a pre-treated 82-year-old patient achieved a progression-free survival of 25 months: a case report.
Wang Y; Li J; Xu Q; Li K; Zhang C; Chen P
J Gastrointest Oncol; 2022 Oct; 13(5):2667-2671. PubMed ID: 36388671
[TBL] [Abstract][Full Text] [Related]
19. Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, Phase III trial.
Xu R; Qin S; Guo W; Bai Y; Deng Y; Yang L; Chen Z; Zhong H; Pan H; Shu Y; Yuan Y; Zhou J; Xu N; Liu T; Ma D; Wu C; Cheng Y; Xu J; Chen D; Li W; Sun S; Yu Z; Cao P; Li J; Chen H; Wang J; Wang S; Wang H; Wang N; Zhang B; Han R; Su W; Guo X; Li J
Future Oncol; 2021 Apr; 17(11):1339-1350. PubMed ID: 33325251
[TBL] [Abstract][Full Text] [Related]
20. Toripalimab and fruquintinib therapy for colorectal cancer after failed multiline chemotherapies: a case report.
Kong LZ; Zheng Y; Li K
Immunotherapy; 2024 Feb; 16(2):107-114. PubMed ID: 38112011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
